CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma

Video

Naresh Bumma, MD, reviews how he selects between CAR T-cell therapy and bispecific agents for patients with refractory multiple myeloma.

Related Videos
A panel of 4 experts on multiple myeloma
Beth Faiman, CNP, PhD, an expert on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Surbhi Sidana, MD, an expert on multiple myeloma
Related Content